8-K: Kenvue Reports Mixed Results for 2023, Provides 2024 Outlook

Kenvue's full year 2023 saw a 3.3% increase in net sales, while the fourth quarter experienced a 2.7% decrease, with the company providing a mixed outlook for 2024.

Summary

• Kenvue reported a 3.3% increase in net sales for the full year 2023, reaching $15.4 billion, with organic growth of 5.0%.
• Diluted earnings per share for the full year were $0.90, and adjusted diluted earnings per share were $1.29.
• However, the fourth quarter of 2023 saw a 2.7% decrease in net sales to $3.7 billion, with a 2.4% decline in organic growth.
• Fourth quarter diluted earnings per share were $0.17, and adjusted diluted earnings per share were $0.31.
• The company's full year gross profit margin was 56.0%, and adjusted gross profit margin was 58.4%.
• For the fourth quarter, gross profit margin was 55.7%, and adjusted gross profit margin was 59.5%.
• Kenvue expects full year 2024 net sales growth to be between 1.0% and 3.0%, with organic growth between 2.0% and 4.0%.
• The company anticipates a full year 2024 adjusted diluted earnings per share in the range of $1.10 to $1.20.
• Kenvue expects full year 2024 reported interest expense to be approximately $400 million.
• The company projects a full year 2024 effective tax rate between 26.5% and 27.5%, and an adjusted effective tax rate between 25.5% and 26.5%.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive full-year results offset by a weaker fourth quarter and a cautious outlook for 2024. The company is facing headwinds and challenges, but also has strategic plans in place.

Positives

• Full year net sales showed a solid increase of 3.3%, reaching $15.4 billion.
• Organic growth for the full year was a healthy 5.0%.
• Adjusted gross profit margins expanded for both the full year and the fourth quarter.
• The company is focused on strategic priorities for 2024, including strengthening the U.S. Skin Health and Beauty business.
• Kenvue is implementing operating model optimization initiatives expected to generate impact in the second half of 2024.
• The company has a strong portfolio of brands including Aveeno, BAND-AID, Johnsons, Listerine, Neutrogena, and Tylenol.

Negatives

• Fourth quarter net sales decreased by 2.7% to $3.7 billion.
• Organic growth declined by 2.4% in the fourth quarter.
• Volume declines impacted both full year and fourth quarter results, partially due to product discontinuations and softer performance in the U.S. Skin Health and Beauty business.
• The company experienced approximately 110 basis points of foreign currency headwinds for the full year and 70 basis points for the fourth quarter.
• Operating income margin decreased for both the full year and fourth quarter due to separation-related costs.
• The company expects 2024 adjusted operating income margin to be slightly below 2023 due to public company costs and foreign currency headwinds.

Risks

• The company faces potential challenges from a continued challenging macro-economic backdrop.
• There is a possibility of unknowns in seasonal businesses.
• Foreign exchange is expected to be a headwind of approximately one percentage point to reported net sales growth in 2024.
• The company is absorbing a full year of public company costs in 2024, impacting profitability.
• There are risks associated with the company's ability to execute its business development strategy and realize the benefits of the separation from Johnson & Johnson.
• The company faces competition, including technological advances and new products from competitors.
• There are risks related to product efficacy, safety concerns, and potential litigation.

Future Outlook

Kenvue expects full year 2024 net sales growth to be in the range of 1.0% to 3.0%, with organic growth between 2.0% and 4.0%. Adjusted operating income margin is expected to be slightly below 2023, and adjusted diluted earnings per share is projected to be between $1.10 and $1.20. The company anticipates approximately $400 million in interest expense for 2024.

Management Comments

• Thibaut Mongon, Chief Executive Officer, stated that 2023 was a transformational year for Kenvue as they began delivering on their long-term value creation algorithm.
• Thibaut Mongon also mentioned that they enter 2024 with clear strategic priorities as an independent Kenvue, including strengthened plans in their U.S. Skin Health and Beauty business.
• Paul Ruh, Chief Financial Officer, stated that their 2024 priorities are clear, as they accelerate investment behind their brands and expect their operating model optimization initiatives to generate impact in the second half of the year.

Industry Context

Kenvue, as the world's largest pure-play consumer health company, is navigating a complex market with challenges including inflation, supply chain issues, and currency fluctuations. The company's performance is being closely watched by investors and competitors in the consumer health sector.

Comparison to Industry Standards

• Kenvue's full-year organic growth of 5.0% is a solid result, but the fourth quarter decline of 2.4% is concerning and may lag behind some competitors in the consumer health space.
• Companies like Haleon (HLN) and Reckitt Benckiser (RKT) also operate in the consumer health sector and their results will be closely compared to Kenvue's.
• Kenvue's adjusted operating income margin of 22.4% for the full year is a strong result, but the expected slight decrease in 2024 may be a point of concern for investors.
• The company's focus on value realization (price increases) to offset volume declines is a common strategy in the current inflationary environment, but its effectiveness will be closely monitored.
• Kenvue's performance in the U.S. Skin Health and Beauty business is a key area to watch, as underperformance in this segment impacted the fourth quarter results.

Stakeholder Impact

• Shareholders may be concerned about the weaker fourth quarter results and the cautious outlook for 2024.
• Employees may be impacted by the company's operating model optimization initiatives.
• Customers may see changes in product availability and pricing due to portfolio rationalization and value realization strategies.
• Suppliers may be affected by the company's supply chain efficiency initiatives.
• Creditors will be monitoring the company's financial performance and debt levels.

Next Steps

• Kenvue will host a conference call with investors to discuss the fourth quarter results.
• The company will focus on executing its 2024 strategic priorities, including strengthening the U.S. Skin Health and Beauty business.
• Kenvue will continue to implement operating model optimization initiatives.

Key Dates

Keywords

Kenvue, Consumer Health, Financial Results, Net Sales, Organic Growth, Earnings Per Share, Gross Profit Margin, Operating Income, Adjusted EBITDA, 2024 Outlook